Oxford BioTherapeutics stock price, funding rounds, valuation and financials

Oxford BioTherapeutics has raised $21.60 m in total funding. Oxford BioTherapeutics annual revenue was £2.09 m in FY 2018

£2.1 M

Oxford BioTherapeutics Revenue FY, 2018
Oxford BioTherapeutics Net income (FY, 2018)-6.5 M
Oxford BioTherapeutics EBIT (FY, 2018)-6.5 M
Oxford BioTherapeutics Cash, 31-Dec-20183.6 M

Oxford BioTherapeutics Funding

Summary Metrics

Founding Date

2004

Oxford BioTherapeutics total Funding

$21.6 m

Oxford BioTherapeutics latest funding size

$10 m

Time since last funding

5 years ago

Oxford BioTherapeutics investors

Oxford BioTherapeutics's latest funding round in July 2015 was reported to be $10 m. In total, Oxford BioTherapeutics has raised $21.6 m

Oxford BioTherapeutics Income Statement

Annual

GBPFY, 2006FY, 2007FY, 2008FY, 2009FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

427.3k293.8k429.5k2.0m3.0m4.5m2.1m

Cost of goods sold

82.0k125.3k117.2k157.4k480.4k438.6k

Gross profit

345.3k176.7k272.1k1.5m2.6m

Gross profit Margin, %

81%60%63%76%85%

Operating expense total

1.1m1.3m1.5m2.0m8.1m8.8m7.7m

Depreciation and amortization

139.8k

EBITDA

(1.4m)(1.3m)(1.6m)(6.5m)(6.1m)(3.0m)

EBITDA margin, %

(438%)(381%)(322%)(203%)(66%)

EBIT

(728.3k)(1.4m)(1.4m)(1.7m)(6.6m)(6.3m)(3.2m)(6.5m)

EBIT margin, %

(170%)(462%)(400%)(329%)(207%)(69%)(313%)

Interest expense

1.0m

Interest income

Pre tax profit

(773.4k)(1.4m)(1.4m)(1.8m)(6.9m)(7.0m)(3.4m)(7.6m)

Income tax expense

227.0k158.5k187.6k165.2k1.2m964.4k1.1m(1.1m)

Net Income

(546.5k)(1.3m)(1.2m)(1.6m)(5.6m)(6.0m)(2.3m)(6.5m)

Oxford BioTherapeutics Balance Sheet

Annual

GBPFY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

79.3k110.4k37.8k550.7k3.7k577.2k9.2m4.0m2.1m1.2m2.6m821.4k3.1m4.3m3.6m

Accounts Receivable

135.3k15.2k33.4k727.2k958.6k1.2m2.6m2.9m168.5k25.5k3.6k

Inventories

19.3k8.1k8.8k14.1k18.6k17.2k9.7k9.8k9.8k

Current Assets

174.7k250.4k178.3k829.7k364.3k971.6k9.9m5.0m3.4m3.8m5.5m2.4m4.4m5.7m5.1m

PP&E

104.8k93.5k395.1k374.8k582.9k507.7k588.8k1.0m860.6k744.0k556.7k475.0k932.9k790.3k686.9k

Goodwill

237.7k

Total Assets

279.5k343.9k573.4k1.3m1.0m1.6m10.6m6.3m4.5m4.8m6.1m2.9m5.4m6.5m5.8m

Accounts Payable

130.0k208.8k340.0k283.2k10.5m9.4m11.7m14.0m5.5m798.4k449.4k291.1k1.3m

Short-term debt

3.3m

Current Liabilities

200.8k414.0k469.6k449.2k584.8k1.3m10.5m9.4m11.7m14.0m5.5m3.6m2.0m3.9m5.7m

Long-term debt

2.3m

Non-Current Liabilities

41.7k357.3k411.8k542.5k765.9k1.2m1.0m786.1k435.4k465.4k4.8m8.5m5.7m2.5m

Total Debt

10.2k66.0k80.0k5.7m

Total Liabilities

242.5k414.0k826.8k861.0k1.1m2.1m11.6m10.4m12.5m14.4m6.0m8.4m10.6m9.7m8.1m

Common Stock

257.7k509.3k251.8k1.9m2.1m2.7m2.7m2.7m2.7m2.7m2.7m2.7m2.7m2.7m2.7m

Retained Earnings

(16.1m)(6.4m)(12.0m)(18.1m)(20.3m)(26.8m)

Total Equity

37.0k(70.1k)(253.4k)404.6k(111.8k)(511.3k)(998.8k)(4.1m)(7.9m)(9.6m)143.7k(5.5m)(5.2m)(3.2m)(2.3m)

Debt to Equity Ratio

0 x-0.6 x-0.2 x-2.5 x

Debt to Assets Ratio

0 x0.1 x0.1 x1 x

Financial Leverage

7.6 x-4.9 x-2.3 x3.1 x-9.1 x-3.1 x-10.7 x-1.5 x-0.6 x-0.5 x42.8 x-0.5 x-1 x-2 x-2.5 x

Oxford BioTherapeutics Cash Flow

Annual

GBPFY, 2006FY, 2007FY, 2008FY, 2009FY, 2015FY, 2016FY, 2017

Net Income

(546.5k)(1.3m)(1.2m)(1.6m)(5.6m)(6.0m)(2.3m)

Income Taxes Paid

1.2m964.4k

Oxford BioTherapeutics Ratios

GBPFY, 2004

Financial Leverage

7.6 x